<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04817748</url>
  </required_header>
  <id_info>
    <org_study_id>MCBDTMIDT</org_study_id>
    <nct_id>NCT04817748</nct_id>
  </id_info>
  <brief_title>Metabolomics Characterization of Biomarkers of Different Types of Myocardial Infarction in Different Time.</brief_title>
  <acronym>MCBDTMIDT</acronym>
  <official_title>Metabolomics Characterization of Biomarkers of Different Types of Myocardial Infarction in Different Time.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 10th People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To find new biomarkers through Metabonomics Study of different types of myocardial infarction&#xD;
      in Different Time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In recent years, with the deepening understanding of the mechanism of myocardial infarction,&#xD;
      in addition to the early understanding of plaque rupture, plaque erosion and other&#xD;
      mechanisms, studies have found that inflammation, immunity, metabolism and other factors also&#xD;
      play an increasingly important role in the occurrence and development of myocardial&#xD;
      infarction. The LoDoCo2 study published at the 2020 ESC annual meeting and the COLCOT study&#xD;
      previously published confirmed for the first time the therapeutic effect of anti-inflammatory&#xD;
      drug colchicine in chronic coronary disease and acute myocardial infarction. At the same&#xD;
      time, the fourth international definition of myocardial infarction also defines three&#xD;
      different types of acute ST segment elevation myocardial infarction (STEMI), acute non ST&#xD;
      segment elevation myocardial infarction (NSTEMI) and non infarct acute myocardial infarction&#xD;
      (MINOCA). However, there are no clear research results on the mechanism, especially the&#xD;
      mechanism of MINOCA. Therefore, the study of acute myocardial infarction in three groups is&#xD;
      of great significance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 17, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>metabolites molecules</measure>
    <time_frame>6 months</time_frame>
    <description>Detection of small molecular metabolites in blood by liquid chromatography mass spectrometry and gas chromatography mass spectrometry</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Acute ST segment elevation myocardial infarction（STEMI）</arm_group_label>
    <description>the patients' coronary and venous blood were drawn for metabolomics study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute non ST segment elevation myocardial infarction（NSTEMI）</arm_group_label>
    <description>the patients' coronary and venous blood were drawn for metabolomics study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute myocardial infarction with no obstructive coronary atherosclerosis（MINOCA）</arm_group_label>
    <description>the patients' coronary and venous blood were drawn for metabolomics study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with normal coronary artery（NCA)</arm_group_label>
    <description>the patients' coronary and venous blood were drawn for metabolomics study</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood extract plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Different types of myocardial infarction were identified according to the&#xD;
             international definition of myocardial infarction and 2020 guidelines and consensus on&#xD;
             myocardial infarction.&#xD;
&#xD;
          2. Patients with normal coronary arteries were determined according to the results of&#xD;
             coronary angiography.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1.The patient clearly had acute myocardial infarction. 2.The patient's serum cardiac&#xD;
        markers (mainly troponin) were elevated (at least above the upper limit of 99% reference&#xD;
        value) and accompanied by one of the following clinical indicators：&#xD;
&#xD;
          1. Ischemic symptoms&#xD;
&#xD;
          2. New ischemic ECG changes, new ST-T changes or left bundle branch block（LBBB）.&#xD;
&#xD;
          3. Pathological Q wave formation in ECG&#xD;
&#xD;
          4. Imaging evidence showed new loss of myocardial activity or new regional wall motion&#xD;
             abnormalities.&#xD;
&#xD;
          5. The thrombus was confirmed by coronary angiography. 3．The patient had chest pain&#xD;
             symptoms, but coronary angiography showed normal coronary artery (such as intercostal&#xD;
             neuralgia, cervical spondylosis, chest pain of unknown origin, etc.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Refusal to sign informed consent.&#xD;
&#xD;
          2. Surgical treatment was performed in the last three months.&#xD;
&#xD;
          3. Patients with a history of the following diseases or consider the diagnosis of the&#xD;
             following diseases：Stress cardiomyopathy, myocarditis, pericarditis, pneumonia,&#xD;
             pulmonary embolism, aortic dissection.&#xD;
&#xD;
          4. Severe heart failure, grade IV cardiac function.&#xD;
&#xD;
          5. Liver and kidney dysfunction.&#xD;
&#xD;
          6. blood-borne diseases, including HIV / AIDS, hepatitis B, hepatitis C, etc.&#xD;
&#xD;
          7. Patients with a history of malignancies, autoimmune diseases, severe infectious&#xD;
             diseases and trauma.&#xD;
&#xD;
          8. Previous history of myocardial infarction and stroke.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Shanghai Tenth People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Zhang, MD</last_name>
    <phone>18917686332</phone>
    <email>yizshcn@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zheng Liu, MD</last_name>
    <phone>18521526364</phone>
    <email>18521526364@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yi Zhang</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Zhang</last_name>
      <phone>18917686332</phone>
      <email>yizshcn@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Zheng Liu</last_name>
      <phone>18521526364</phone>
      <email>18521526364@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 13, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 10th People's Hospital</investigator_affiliation>
    <investigator_full_name>Ya-Wei Xu</investigator_full_name>
    <investigator_title>cardiology department of shanghai 10th people's hospital</investigator_title>
  </responsible_party>
  <keyword>myocardial infarction</keyword>
  <keyword>metabolomics</keyword>
  <keyword>biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

